Aetion will use this fresh funding to further innovate its platform, expand its footprint in Europe and Asia, and grow its team to keep up with a surge in demand. The company is now hiring, with dozens of open positions at its NYC HQ and offices in Boston and LA.
This latest funding round comes about a year after ElevateBio announced a $170 million Series B. The money will be used to expand its R&D and manufacturing capabilities, and spin out new companies and partnerships based on that research.
Embark’s tests can be used to help determine over 200 genetic health risks for your dog. After a test is complete, pet owners can create personalized care plans for their dogs based on their genetic profile.
